Código QR

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?

ABSTRACT Migraine is a prevalent disorder and a cause of high disability, influenced by modifiable and non-modifiable risk factors. Comorbid and psychiatric illnesses are prevalent in migraine patients and should be considered when choosing preventive drugs. There have been unforeseen problems with...

Descrición completa

Gardado en:
Autor Principal: Caio Vinicius de Meira Grava Simioni
Formato: Artigo
Idioma:Inglês
Publicado: Thieme Revinter Publicações 2022-08-01
Series:Arquivos de Neuro-Psiquiatria
Assuntos:
Antibodies, Monoclonal
Costs and Cost Analysis
Efficacy
Health Services Needs and Demand
Migraine Disorders
Headache
Pharmaceutical Preparations
Prescriptions
Safety
Surveillance
Therapeutics
Acceso en liña:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2022000700214&tlng=en
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares